The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms
Cognitive impairment is a prevalent non-motor symptom of Parkinson’s disease (PD), increasing the risk of dementia as the disease progresses. Despite its clinical significance, the etiology of cognitive impairment in PD remains unclear. Apolipoprotein E4 (APOE4), a well-known genetic risk factor of...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2025.1515374/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025473515454464 |
|---|---|
| author | Angenelle Eve Rosal Angenelle Eve Rosal Sarah L. Martin Sarah L. Martin Antonio P. Strafella Antonio P. Strafella Antonio P. Strafella |
| author_facet | Angenelle Eve Rosal Angenelle Eve Rosal Sarah L. Martin Sarah L. Martin Antonio P. Strafella Antonio P. Strafella Antonio P. Strafella |
| author_sort | Angenelle Eve Rosal |
| collection | DOAJ |
| description | Cognitive impairment is a prevalent non-motor symptom of Parkinson’s disease (PD), increasing the risk of dementia as the disease progresses. Despite its clinical significance, the etiology of cognitive impairment in PD remains unclear. Apolipoprotein E4 (APOE4), a well-known genetic risk factor of Alzheimer’s disease, has been studied for its potential role in PD-related cognitive impairment. However, findings have been conflicting and thus inconclusive, highlighting a need to critically evaluate the current research. Several studies using neuroimaging modalities have explored the brains of individuals with PD and atypical parkinsonian disorders who have APOE4. Some of these studies have identified distinct neuropathological changes that have been previously reported to be associated with cognitive impairments in those with Parkinsonisms. Here, we review the role of APOE4 on cognitive impairment in PD and atypical Parkinsonisms using neuroimaging evidence. We will examine how APOE4 may contribute to pathological changes within the brain and its association with cognitive impairment. |
| format | Article |
| id | doaj-art-e471fe0e572f49ac935ae8da70f8e518 |
| institution | DOAJ |
| issn | 1662-453X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj-art-e471fe0e572f49ac935ae8da70f8e5182025-08-20T03:00:50ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2025-02-011910.3389/fnins.2025.15153741515374The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and ParkinsonismsAngenelle Eve Rosal0Angenelle Eve Rosal1Sarah L. Martin2Sarah L. Martin3Antonio P. Strafella4Antonio P. Strafella5Antonio P. Strafella6Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, CanadaInstitute of Medical Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CanadaBrain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, CanadaTranslation and Computational Neurosciences Unit (TCNU), Faculty of Health and Education, Manchester Metropolitan University, Manchester, United KingdomBrain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, CanadaInstitute of Medical Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, CanadaEdmond J. Safra Parkinson Disease Program, Neurology Division, Toronto Western Hospital and Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, CanadaCognitive impairment is a prevalent non-motor symptom of Parkinson’s disease (PD), increasing the risk of dementia as the disease progresses. Despite its clinical significance, the etiology of cognitive impairment in PD remains unclear. Apolipoprotein E4 (APOE4), a well-known genetic risk factor of Alzheimer’s disease, has been studied for its potential role in PD-related cognitive impairment. However, findings have been conflicting and thus inconclusive, highlighting a need to critically evaluate the current research. Several studies using neuroimaging modalities have explored the brains of individuals with PD and atypical parkinsonian disorders who have APOE4. Some of these studies have identified distinct neuropathological changes that have been previously reported to be associated with cognitive impairments in those with Parkinsonisms. Here, we review the role of APOE4 on cognitive impairment in PD and atypical Parkinsonisms using neuroimaging evidence. We will examine how APOE4 may contribute to pathological changes within the brain and its association with cognitive impairment.https://www.frontiersin.org/articles/10.3389/fnins.2025.1515374/fullApolipoprotein E4ParkinsonismDLBcognitive impairmentneuroimagingParkinson’s disease |
| spellingShingle | Angenelle Eve Rosal Angenelle Eve Rosal Sarah L. Martin Sarah L. Martin Antonio P. Strafella Antonio P. Strafella Antonio P. Strafella The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms Frontiers in Neuroscience Apolipoprotein E4 Parkinsonism DLB cognitive impairment neuroimaging Parkinson’s disease |
| title | The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms |
| title_full | The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms |
| title_fullStr | The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms |
| title_full_unstemmed | The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms |
| title_short | The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms |
| title_sort | role of apolipoprotein e4 on cognitive impairment in parkinson s disease and parkinsonisms |
| topic | Apolipoprotein E4 Parkinsonism DLB cognitive impairment neuroimaging Parkinson’s disease |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2025.1515374/full |
| work_keys_str_mv | AT angenelleeverosal theroleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT angenelleeverosal theroleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT sarahlmartin theroleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT sarahlmartin theroleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT antoniopstrafella theroleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT antoniopstrafella theroleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT antoniopstrafella theroleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT angenelleeverosal roleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT angenelleeverosal roleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT sarahlmartin roleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT sarahlmartin roleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT antoniopstrafella roleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT antoniopstrafella roleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms AT antoniopstrafella roleofapolipoproteine4oncognitiveimpairmentinparkinsonsdiseaseandparkinsonisms |